Clinical experience with omalizumab in children with bronchial asthma
Anti-IgE therapy is pathogenetically justified and aimed at prevention of acute allergic inflammation. The article presents the experience of curing children with severe bronchial asthma with Omalizumab in addition to basic therapy. The clinical course of the disease during six months of observation was analyzed. The positive dynamics was shown, including the reliable decrease in the frequency of hospitalizations for acute asthma exacerbations and a possibility to reduce the basic doses of drugs without clinical compromise. It should be highlighted that the clinical improvement of the disease course directly correlated with the reliable results of pulmonary function tests. No side effects of Omalizumab were observed.